These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8419482)

  • 1. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers.
    Newcomb JR; Cresswell P
    J Immunol; 1993 Jan; 150(2):499-507. PubMed ID: 8419482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DR alpha beta dimers released from complexes with invariant chain fail to stimulate alloreactive T cell clones.
    Demotz S
    Eur J Immunol; 1993 Sep; 23(9):2100-8. PubMed ID: 8370392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
    Lamb CA; Cresswell P
    J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
    Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
    Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
    Long EO; LaVaute T; Pinet V; Jaraquemada D
    J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
    Khalil H; Brunet A; Thibodeau J
    J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
    Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
    J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of naturally processed peptides bound to HLA-DR4, DR53 (DRB1*0405, DRB4*0101)].
    Kinouchi R; Katagiri M
    Hokkaido Igaku Zasshi; 1995 Jan; 70(1):175-81. PubMed ID: 7744365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes.
    Siebenkotten IM; Carstens C; Koch N
    J Immunol; 1998 Apr; 160(7):3355-62. PubMed ID: 9531295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DR/CLIP (class II-associated invariant chain peptides) and DR/peptide complexes colocalize in prelysosomes in human B lymphoblastoid cells.
    Stang E; Guerra CB; Amaya M; Paterson Y; Bakke O; Mellins ED
    J Immunol; 1998 May; 160(10):4696-707. PubMed ID: 9590215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid nonlysosomal degradation of assembled HLA class II glycoproteins incorporating a mutant DR alpha-chain.
    Koppelman B; Cresswell P
    J Immunol; 1990 Oct; 145(8):2730-6. PubMed ID: 2212658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invariant chain associates with HLA class II antigens via its extracytoplasmic region.
    Marks MS; Cresswell P
    J Immunol; 1986 Apr; 136(7):2519-25. PubMed ID: 3512715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel domain on HLA-DRbeta chain regulates the chaperone role of the invariant chain.
    Neumann J; Koch N
    J Cell Sci; 2006 Oct; 119(Pt 20):4207-14. PubMed ID: 16984974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DR beta chain residue 86 controls DR alpha beta dimer stability.
    Verreck FA; Termijtelen A; Koning F
    Eur J Immunol; 1993 Jun; 23(6):1346-50. PubMed ID: 8500529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor.
    Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG
    Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens.
    Machamer CE; Cresswell P
    J Immunol; 1982 Dec; 129(6):2564-9. PubMed ID: 6982931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.